Company Overview and News

0
ASX has steady week as trade tensions strengthen $US

2018-07-13 theage.com.au
The Australian sharemarket has closed the week flat, following days of turbulent trading as the US-China trade saga continues to leave investors uncertain.
PLS RSG PILBF DB RMGGY RMGGF

0
ASX has steady week as trade tensions strengthen $US

2018-07-13 smh.com.au
The Australian sharemarket has closed the week flat, following days of turbulent trading as the US-China trade saga continues to leave investors uncertain.
PLS RSG PILBF DB RMGGY RMGGF

0
An Update On Pilbara Minerals

2018-07-12 seekingalpha
Pilbara Minerals has progressed exceptionally well from when I last wrote on them in May 2017.
PLS PILBF AGO ATLGF AGODY

0
ASIC extends Atlas deadline for Hancock takeover offer response

2018-07-12 australianmining.com.au
The Australian Securities and Investments Commission (ASIC) has granted Atlas Iron relief regarding the deadline of its target statement in response to a $390 million takeover offer from Gina Rinehart-owned Hancock Prospecting.
PLS PILBF AGO ATLGF AGODY MALRY MALRF MIN

1
ASX starts the week higher, shrugging off tariff concerns

2018-07-09 theage.com.au
The Australian sharemarket has begun the week modestly higher as markets across Asia shrugged off trade tariff concerns.
PILBF BLT MS.PRE MS.PRF MS.PRG RDSB IGO RDSA MS.PRA IFGNF GALXF MS RYDAF PLS RDS.B RDS.A IDX BHPBF IFN IIDDY GXY MS.PRI BHP MS.PRK RYDBF BBL BHP BHPLF

1
ASX starts the week higher, shrugging off tariff concerns

2018-07-09 smh.com.au
The Australian sharemarket has begun the week modestly higher as markets across Asia shrugged off trade tariff concerns.
PILBF BLT MS.PRE MS.PRF MS.PRG RDSB IGO RDSA MS.PRA IFGNF GALXF MS RYDAF PLS RDS.B RDS.A IDX BHPBF IFN IIDDY GXY MS.PRI BHP MS.PRK RYDBF BBL BHP BHPLF

2
Australian shares advance on strength of major banks

2018-07-03 theage.com.au
The Australian sharemarket has recorded only its second advance in the last eight sessions despite a broad retreat of commodity prices overnight.
PILBF RIO DB BLT RIO IAG MS.PRE MS.PRF MS.PRG MS.PRA BEPTF RTPPF GALXF RTNTF MS TWE SML IAUGY PLS TSRYY BHPBF EBOSY EBO BCHEY BPT EBOSF TSRYF GXY IAUGF MS.PRI BHP RIO MS.PRK BBL BHP BHPLF EBO

2
Australian shares advance on strength of major banks

2018-07-03 smh.com.au
The Australian sharemarket has recorded only its second advance in the last eight sessions despite a broad retreat of commodity prices overnight.
PILBF RIO DB BLT RIO IAG MS.PRE MS.PRF MS.PRG MS.PRA BEPTF RTPPF GALXF RTNTF MS TWE SML IAUGY PLS TSRYY BHPBF EBOSY EBO BCHEY BPT EBOSF TSRYF GXY IAUGF MS.PRI BHP RIO MS.PRK BBL BHP BHPLF EBO

1
Lithium targets identified at Pilgangoora

2018-07-03 australianmining.com.au
Metalicity has identified new lithium targets at the Pilgangoora North lithium project, which is 10km from Altura Mining and Pilbara Minerals’ projects in the Pilbara, Western Australia.
PLS PILBF ALTAF AJM

102
Lithium's Top Challenge Is Finding Funds, Not the Battery Metal - Bloomberg

2018-07-02 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
PILBF C.WSA BNPQY MS.PRE MS.PRF MS.PRG 2333 MS.PRA NMKEF C.WS.B GALXF ALTAF NMX C.WS.A C.PRP C.PRU MS C.PRS PLS KDR C C.PRL NHPEF C.PRJ C.PRK BNPQF C.PRG C.PRC VLKAF BNPZY GXY MS.PRI C.PRPCL MS.PRK CGBBW AJM

17
Big-name companies leave investors nursing financial bruises in 2018

2018-07-01 theage.com.au
This past weekend should have been party time for Australia’s sharemarket investors. In the 2018 financial year, the S&P/ASX 200 index rewarded investors with a booming total return of around 16 per cent. But you had to invest smart.
PLS MQBKY PILBF RIO RMYHY RIO LYSCF WTCHF MCQEF MAYNF BCHEY BEPTF BPT RTPPF RIO RHC LYSDY RTNTF MQG RMSYF

17
Big-name companies leave investors nursing financial bruises in 2018

2018-07-01 smh.com.au
This weekend should be party time for Australia’s sharemarket investors. In the 2018 financial year, the S&P/ASX 200 index rewarded investors with a booming total return of around 16 per cent. But you had to invest smart.
PLS MQBKY PILBF RIO RMYHY RIO LYSCF WTCHF MCQEF MAYNF BCHEY BEPTF BPT RTPPF RIO RHC LYSDY RTNTF MQG RMSYF

1
Pilbara Minerals delivers first concentrate at Pilgangoora

2018-06-21 australianmining.com.au
The production of spodumene and tantalum concentrates marks another key step towards full production at Pilgangoora.
PLS PILBF AGO ATLGF AGODY

140
It's Electric: Key Growth Investing Trends To Watch

2018-06-19 seekingalpha
Electric vehicles have a long road ahead of them, even if Tesla sees a few twists and turns along the way.
PILBF SSNLF CCZ RNSDF HAV GALXF ALTAF GM.WS.A GM.WS.B GM.WS.C GM VLKAY PLS AYR BC94 SMSN BSWQY DDAIF TWNAF KATFF GXY KAT TAW GOOGL MU GM.WSB AJM SMSD

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: Q7539C100